Rock the Casma

Why Third Rock thinks the time is right to invest in autophagy with newco Casma

The recent discovery of autophagy-inducing targets led Third Rock Ventures to launch Casma Therapeutics Inc. with a $58.5 million series A to develop therapeutics that promote autophagy and ameliorate cellular distress in inflammatory, neurodegenerative, muscular and lysosomal storage diseases.

Autophagy is a process

Read the full 421 word article

User Sign In